Cure My Disease

Don't miss your cure!

 Log in / Sign up

Less contrast, same clarity: new MRI method could reduce gadolinium exposure

NCT ID NCT04113395

Completed Diagnosis Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether using a much lower dose of gadolinium (a contrast dye) in MRI scans can still find meningiomas (a type of brain tumor) as well as the standard full dose. Over 500 adults getting a brain MRI for screening or follow-up took part. The goal is to reduce the amount of gadolinium patients receive, which can build up in the body over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENINGIOMA

Contacts and locations

Locations

  • CHU de Bordeaux

    Bordeaux, 33076, France

  • CHU de Grenoble

    Grenoble, Grenoble, 38100, France

  • CHU de Limoges

    Limoges, Limoges, 87042, France

  • CHU de Lyon

    Lyon, Lyon, 69495, France

  • CHU de Nantes

    Nantes, Nantes, 44800, France

  • CHU de Rennes

    Rennes, Rennes, 35033, France

  • CHU de Rouen

    Rouen, Rouen, 76000, France

  • CHU de Strasbourg

    Strasbourg, Strasbourg, 67000, France

  • CHU de Tours

    Tours, Tours, France

  • Fondation ophtalmique Adolphe de Rothschild

    Paris, Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.